Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2020 2
2021 7
2022 10
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Infliximab and Tofacitinib Attenuate Neutralizing Antibody Responses Against SARS-CoV-2 Ancestral and Omicron Variants in Inflammatory Bowel Disease Patients After 3 Doses of COVID-19 Vaccine.
Liu Z, Alexander JL, Lin KW; VIP Study Investigators; Ahmad T, Pollock KM, Powell N. Liu Z, et al. Gastroenterology. 2023 Feb;164(2):300-303.e3. doi: 10.1053/j.gastro.2022.10.010. Epub 2022 Oct 19. Gastroenterology. 2023. PMID: 36270334 Free PMC article. No abstract available.
Plasma proteomic signature predicts who will get persistent symptoms following SARS-CoV-2 infection.
Captur G, Moon JC, Topriceanu CC, Joy G, Swadling L, Hallqvist J, Doykov I, Patel N, Spiewak J, Baldwin T, Hamblin M, Menacho K, Fontana M, Treibel TA, Manisty C, O'Brien B, Gibbons JM, Pade C, Brooks T, Altmann DM, Boyton RJ, McKnight Á, Maini MK, Noursadeghi M, Mills K, Heywood WE; UK COVIDsortium Investigators. Captur G, et al. EBioMedicine. 2022 Nov;85:104293. doi: 10.1016/j.ebiom.2022.104293. Epub 2022 Sep 28. EBioMedicine. 2022. PMID: 36182629 Free PMC article.
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.
Alexander JL, Liu Z, Muñoz Sandoval D, Reynolds C, Ibraheim H, Anandabaskaran S, Saifuddin A, Castro Seoane R, Anand N, Nice R, Bewshea C, D'Mello A, Constable L, Jones GR, Balarajah S, Fiorentino F, Sebastian S, Irving PM, Hicks LC, Williams HRT, Kent AJ, Linger R, Parkes M, Kok K, Patel KV, Teare JP, Altmann DM, Goodhand JR, Hart AL, Lees CW, Boyton RJ, Kennedy NA, Ahmad T, Powell N; VIP study investigators. Alexander JL, et al. Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9. Lancet Gastroenterol Hepatol. 2022. PMID: 36088954 Free PMC article.
Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, Michell S, Kok KB, Lamb CA, Smith PJ, Hart AL, Pollok RC, Lees CW, Boyton RJ, Altmann DM, Sebastian S, Powell N, Goodhand JR, Ahmad T. Kennedy NA, et al. Gut. 2023 Feb;72(2):295-305. doi: 10.1136/gutjnl-2022-327570. Epub 2022 Jul 28. Gut. 2023. PMID: 35902214
Immune boosting by B.1.1.529 (Omicron) depends on previous SARS-CoV-2 exposure.
Reynolds CJ, Pade C, Gibbons JM, Otter AD, Lin KM, Muñoz Sandoval D, Pieper FP, Butler DK, Liu S, Joy G, Forooghi N, Treibel TA, Manisty C, Moon JC; COVIDsortium Investigators§; COVIDsortium Immune Correlates Network§; Semper A, Brooks T, McKnight Á, Altmann DM, Boyton RJ, Abbass H, Abiodun A, Alfarih M, Alldis Z, Altmann DM, Amin OE, Andiapen M, Artico J, Augusto JB, Baca GL, Bailey SNL, Bhuva AN, Boulter A, Bowles R, Boyton RJ, Bracken OV, O'Brien B, Brooks T, Bullock N, Butler DK, Captur G, Carr O, Champion N, Chan C, Chandran A, Coleman T, Couto de Sousa J, Couto-Parada X, Cross E, Cutino-Moguel T, D'Arcangelo S, Davies RH, Douglas B, Di Genova C, Dieobi-Anene K, Diniz MO, Ellis A, Feehan K, Finlay M, Fontana M, Forooghi N, Francis S, Gibbons JM, Gillespie D, Gilroy D, Hamblin M, Harker G, Hemingway G, Hewson J, Heywood W, Hickling LM, Hicks B, Hingorani AD, Howes L, Itua I, Jardim V, Lee WJ, Jensen M, Jones J, Jones M, Joy G, Kapil V, Kelly C, Kurdi H, Lambourne J, Lin KM, Liu S, Lloyd A, Louth S, Maini MK, Mandadapu V, Manisty C, McKnight Á, Menacho K, Mfuko C, Mills K, Millward S, Mitchelmore O, Moon C, Moon J, Muñoz Sandoval D, Murray SM, Noursadeghi M, Otter A, Pade C, Pa… See abstract for full author list ➔ Reynolds CJ, et al. Science. 2022 Jul 15;377(6603):eabq1841. doi: 10.1126/science.abq1841. Epub 2022 Jul 15. Science. 2022. PMID: 35699621 Free PMC article.
Rapid synchronous type 1 IFN and virus-specific T cell responses characterize first wave non-severe SARS-CoV-2 infections.
Chandran A, Rosenheim J, Nageswaran G, Swadling L, Pollara G, Gupta RK, Burton AR, Guerra-Assunção JA, Woolston A, Ronel T, Pade C, Gibbons JM, Sanz-Magallon Duque De Estrada B, Robert de Massy M, Whelan M, Semper A, Brooks T, Altmann DM, Boyton RJ, McKnight Á, Captur G, Manisty C, Treibel TA, Moon JC, Tomlinson GS, Maini MK, Chain BM, Noursadeghi M; COVIDsortium Investigators. Chandran A, et al. Cell Rep Med. 2022 Mar 4;3(3):100557. doi: 10.1016/j.xcrm.2022.100557. eCollection 2022 Mar 15. Cell Rep Med. 2022. PMID: 35474751 Free PMC article.
Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin KM, Butler DK, Chanchlani N, Nice R, Chee D, Bewshea C, Janjua M, McDonald TJ, Sebastian S, Alexander JL, Constable L, Lee JC, Murray CD, Hart AL, Irving PM, Jones GR, Kok KB, Lamb CA, Lees CW, Altmann DM, Boyton RJ, Goodhand JR, Powell N, Ahmad T; CLARITY IBD study. Lin S, et al. Nat Commun. 2022 Mar 16;13(1):1379. doi: 10.1038/s41467-022-28517-z. Nat Commun. 2022. PMID: 35296643 Free PMC article.
HLA-DR polymorphism in SARS-CoV-2 infection and susceptibility to symptomatic COVID-19.
Astbury S, Reynolds CJ, Butler DK, Muñoz-Sandoval DC, Lin KM, Pieper FP, Otter A, Kouraki A, Cusin L, Nightingale J, Vijay A, Craxford S, Aithal GP, Tighe PJ, Gibbons JM, Pade C, Joy G, Maini M, Chain B, Semper A, Brooks T, Ollivere BJ, McKnight Á, Noursadeghi M, Treibel TA, Manisty C, Moon JC; COVIDsortium Investigators*; Valdes AM, Boyton RJ, Altmann DM. Astbury S, et al. Immunology. 2022 May;166(1):68-77. doi: 10.1111/imm.13450. Epub 2022 Mar 8. Immunology. 2022. PMID: 35156709 Free PMC article.
Heterologous infection and vaccination shapes immunity against SARS-CoV-2 variants.
Reynolds CJ, Gibbons JM, Pade C, Lin KM, Sandoval DM, Pieper F, Butler DK, Liu S, Otter AD, Joy G, Menacho K, Fontana M, Smit A, Kele B, Cutino-Moguel T, Maini MK, Noursadeghi M; COVIDsortium Immune Correlates Network‡; Brooks T, Semper A, Manisty C, Treibel TA, Moon JC; COVIDsortium Investigators‡; McKnight Á, Altmann DM, Boyton RJ. Reynolds CJ, et al. Science. 2022 Jan 14;375(6577):183-192. doi: 10.1126/science.abm0811. Epub 2021 Dec 2. Science. 2022. PMID: 34855510 Free PMC article.
Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2.
Swadling L, Diniz MO, Schmidt NM, Amin OE, Chandran A, Shaw E, Pade C, Gibbons JM, Le Bert N, Tan AT, Jeffery-Smith A, Tan CCS, Tham CYL, Kucykowicz S, Aidoo-Micah G, Rosenheim J, Davies J, Johnson M, Jensen MP, Joy G, McCoy LE, Valdes AM, Chain BM, Goldblatt D, Altmann DM, Boyton RJ, Manisty C, Treibel TA, Moon JC; COVIDsortium Investigators; van Dorp L, Balloux F, McKnight Á, Noursadeghi M, Bertoletti A, Maini MK. Swadling L, et al. Nature. 2022 Jan;601(7891):110-117. doi: 10.1038/s41586-021-04186-8. Epub 2021 Nov 10. Nature. 2022. PMID: 34758478 Free PMC article.
17 results